 Home > Medical News > Medicines Company News > Ganxi Biologics announced that the Phase 1/2 registration clinical trial of GC007g for the treatment of B-ALL has successfully entered the Phase 2 study phase and has completed the dosing of the first patient

Ganxi Biologics announced that the Phase 1/2 registration clinical trial of GC007g for the treatment of B-ALL has successfully entered the Phase 2 study phase and has completed the dosing of the first patient

 Last Update: 2022-10-25
 Source: Internet
 Author: User

Tags

what stationary phase

car cell therapy companies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Global clinical-stage biopharmaceutical company Ganxi Biotechnology Group (NASDAQ: GRCL; "Ganxi Biologics") announced that the Phase 1/2 registration clinical trial in China to comprehensively evaluate the efficacy of GC007g in the treatment of relapsed/refractory acute B-cell leukemia (r/r B-ALL) has successfully entered the Phase 2 study stage, and the first enrolled patient has been dosed
.

GC007g is a donor-derived allogeneic CAR-T cell therapy targeting CD19 under Ganxi Biologics for the treatment of patients with B-ALL who have relapsed after allogeneic stem cell transplantation
.
This allogeneic cell therapy is prepared using T cells from healthy donors matched with human leukocyte antigen (HLA), providing an alternative to patients who are not eligible for autologous CAR-T therapy due to poor autologous T cell health, infection, or other reasons
.

In phase 1 clinical trials, GC007g has achieved encouraging data
on efficacy and safety.
The Company is continuing to conduct a registrational Phase 2 clinical trial in China to further evaluate the efficacy and safety
of GC007g in patients with r/r B-ALL at the recommended Phase 2 dose.

"Currently, patients with B-ALL who relapse after allogeneic stem cell transplantation often have a poor prognosis and there is a clear clinically unmet need
.
Donor-derived allogeneic CAR-T therapy is expected to bring new treatment options and hope to some patients who are not suitable for other treatments, including autologous CAR-T therapy," said Dr.
Wenling Li, Chief Medical Officer of Ganxi Biologics, "We believe that GC007g will be expected to become the first donor-derived allogeneic CAR-T therapy of its kind in China to benefit patients
.
" At the same time, GC007g is also the first product candidate to officially enter the registration clinical trial, which is a milestone for the rapid development of the company and encourages the team to continue to pursue
the innovation of cell therapy.
"

About GC007g

GC007g is a donor-derived allogeneic CAR-T cell therapy targeting CD19 that is prepared
using HLA-matched T cells from healthy donors.
Currently, the product candidate is undergoing a Phase 1/2 registrational clinical trial in China to evaluate its efficacy
in patients with B-ALL who have relapsed after allogeneic transplantation and are not eligible for autologous CAR-T therapy.

About Acute Lymphoblastic Leukemia (ALL)

Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by abnormal proliferation of immature lymphocytes in the bone marrow, usually including acute T-lymphoblastic leukemia (T-ALL) or acute B-lymphoblastic leukemia (B-ALL).

Approximately 64,000 patients worldwide are diagnosed with ALL each year; In 2022, approximately 6,660 ^[1] patients in the United States are expected to be diagnosed with ALL; In China, this number is about 7,400^[2] (latest published data in 2020).

Among adult patients, B-ALL patients account for about 75%
of all ALL patients.

[1] data source: American Cancer Society

[2] data source: Clarivate | DRG: Acute Lymphoblastic Leukemia - Epidemiology

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.